Tuesday June 21, 2022
With both winners and losers as a result of Covid-19, we’ll review the current status of the diagnostic lab market. As we look ahead and anticipate revenues to fall back in line with pre-Covid levels, what is the investor viewpoint? What strategies are operators employing to manage profitability and drive growth? How fast are sub-sectors such as B2C, genetic and outsourcing growing?
Hamish Grierson, CEO and Co-Founder, Thriva
David Wells, CEO, IBMS
Chris Fourie, Associate Director, Lifecycle
Moderated by Kirsty Withams, Head of Intelligence, Healthcare Business International
St James - 4th Floor
Explore similar sessions
Covid has created huge extra demand for mental health services. How far can this be met by digital therapeutics and how can operators consolidate this fragmented sector? And how far...
Primary Care PLUS
The huge primary care sector in Europe holds the key to outpatient consolidation. Here we look at how operators are pairing it with digital and telehealth, pharmacies and imaging. And...
The effects of Covid-19 have had a more lasting impact in dentistry vs other sectors. We’ll ask our panel to outline the next opportunities for growth. How are operators adapting...